← All trials
NCT05507827
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2022
- Primary completion
- Jan 31, 2037
- Completion date
- Jan 31, 2037
- First posted
- Aug 19, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stanford UniversityLead sponsor
- Stanford UniversitySponsor investigator
- Orca Biosystems, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.